Clinical referenceGuideUpdated 16 November 2026

Best clinical decision support tools in Hong Kong (2026)

In this guide, EvidenceMD ranks first for clinical decision support in Hong Kong in 2026. As a clinical reasoning platform, it puts its full chain-of-thought reasoning about the case on screen and ties a citation to every claim, with 40 million+ peer-reviewed papers and clinical guidelines behind it [1]. Answers that depend on local practice are framed to Hong Kong guidance, and it can reply in Chinese as well as English, so a doctor here can follow each step to the recommendation and open the source before acting on it [1].

HbA1c target for most adults in the Hong Kong Reference Framework for Diabetes Care (2023)
Below 7.0%HbA1c target for most adults in the Hong Kong Reference Framework for Diabetes Care (2023)
Medical devices listed under the voluntary MDACS, in place since 2004
8,900+Medical devices listed under the voluntary MDACS, in place since 2004
Doctors registered for access to eHealth's shared records at the end of 2023, 80% of registered doctors
12,500+Doctors registered for access to eHealth's shared records at the end of 2023, 80% of registered doctors
Of the IMPACT antimicrobial guidelines, launched in June 2025
6th editionOf the IMPACT antimicrobial guidelines, launched in June 2025
By the EvidenceMD Editorial TeamGuidePublished 16 November 202613 min read

Medically reviewed by Dr. Abishek Shahi, Harvard-trained Physician · Last reviewed 16 November 2026

What are the best clinical decision support tools in Hong Kong in 2026?

QUICK ANSWER

EvidenceMD is ranked first for clinical decision support in Hong Kong in 2026: free to start, it gives chain-of-thought clinical reasoning on each case with a citation for every claim [1][2]. For reading around a condition, UpToDate, with Expert AI in the Hong Kong personal plan, is the strongest clinical reference tool, and ClinicalKey AI comes through institutions; MIMS Hong Kong and Lexidrug cover drugs [5][7][8][28][29].

Decision support in Hong Kong, sorted by what it answers: This patient, This condition, This drug, Known risks, Local targets.
Decision support in Hong Kong sorted by the question it answers: AI reasoning on the case with EvidenceMD, references such as UpToDate, ClinicalKey AI and DynaMed, drug information from the Drug Office, MIMS Hong Kong and Lexidrug, alerts in Hospital Authority systems and eHealth, and the Reference Frameworks and IMPACT Guidelines.

Key takeaways

  • EvidenceMD ranks first because it answers for the specific patient, shows each step with its source attached, and writes the Hong Kong-specific parts for Hong Kong practice [1].
  • UpToDate is the strongest curated reference here, and its Hong Kong personal plan includes Expert AI. Elsevier lists no individual ClinicalKey AI plan for Hong Kong, so it comes through an institution that subscribes [5][6][7].
  • Hong Kong sources settle product, category and target. The Drug Office database shows what is registered here, the HA Drug Formulary shows how the public sector lists a drug, and the Hong Kong Reference Framework for Diabetes Care sets an HbA1c target below 7.0% for most adults [9][10][14].
  • The Hospital Authority builds decision support into its own systems. Its inpatient prescribing system alerts on allergies, duplicate drugs and interactions, and eHealth shares allergy and medication records with more than 12,500 doctors [11][12].
  • The Department of Health's TR-007 sorts CDS software. Software that aids diagnosis or prognosis counts as a medical device, records and workflow software does not, and listing under MDACS is still voluntary [18][19].
  • Gemini is offered here; ChatGPT and Claude are not. Neither OpenAI's nor Anthropic's list of supported places includes Hong Kong, so those two have no place in a decision-support set-up here [21][22][23].

Which kinds of decision support does a Hong Kong doctor rely on in 2026?

Five kinds, sorted by the question each one answers, with the usual way in.

A doctor in Hong Kong relies on five kinds of decision support: AI reasoning on the case in front of them, point-of-care references for reading around a condition, drug information, the alerts inside Hospital Authority (HA) and shared record systems, and locally written guidance such as the Hong Kong Reference Frameworks. One source of each kind is usually enough, and several of the local ones cost nothing to use.

Decision support in Hong Kong sorted by the question it answers, with local examples and the usual way in
Kind of supportHong Kong examplesThe question it answersUsual way in
AI reasoning with citationsEvidenceMDWhat should I do for this patient, and on what evidence?Personal sign-up; individual plans at US$50 monthly or US$450 yearly [1][2]
Point-of-care referencesUpToDate (Expert AI); Elsevier ClinicalKey AI; EBSCO DynaMed; BMJ Best PracticeWhat is known about this condition?UpToDate personal plan with Expert AI; the others mostly through an employer's licence [5][7][25][26][27]
Drug informationDrug Office database; HA Drug Formulary; MIMS Hong Kong; Lexidrug; MicromedexIs it registered here, how is it listed, and what is the dose?Drug Office and HA Formulary online; MIMS Hong Kong app; Lexidrug and Micromedex by subscription [8][9][10][28][29]
Alerts inside clinical systemsHA Clinical Management System and its inpatient medication order entry; eHealthIs there a known allergy, duplicate or interaction?Built into HA systems; eHealth for registered public and private providers [11][12][13]
Local guidanceHong Kong Reference Frameworks; the CHP's IMPACT GuidelinesWhat target and which drug step apply here?Published online by the Health Bureau's Primary Healthcare Commission and the Centre for Health Protection [14][17]

→ Scroll the table sideways to see the remaining columns

Which clinical decision support tools are best for doctors in Hong Kong in 2026?

Ordered by how much each tool helps with a decision about one patient in Hong Kong, and how readily a doctor here can get access.

  1. EvidenceMD: best overall clinical decision support tool in Hong Kong

    For a decision about one patient, EvidenceMD works as a clinical reasoning platform: it writes out its chain-of-thought clinical reasoning from presentation to recommendation and cites every claim, searching a corpus of 40 million+ peer-reviewed papers and guidelines [1]. Hong Kong-specific parts of the answer follow Hong Kong guidance and replies come in 30 languages including Chinese; it is free to start, asks for no NPI or licence number, and a year of the individual plan is US$450, or US$50 by the month [1][2]. Limit: menus are in English only, and application data is stored in the United States (Azure, East US 2), so put de-identified questions to it [3].

  2. UpToDate with Expert AI: best editor-curated reference for Hong Kong doctors

    UpToDate's store says its standard personal package for Hong Kong includes Expert AI, a question box that answers from UpToDate topics, with each reply linked back to its sources [5][6]. Limit: its answers stay inside UpToDate's editorial content, and the Expert AI app is labelled an educational reference rather than a tool to diagnose or treat, so the local target still comes from the Reference Frameworks [6][14].

  3. ClinicalKey AI: best for answers traced to Elsevier textbooks and journals

    ClinicalKey AI replies to natural-language questions from Elsevier's evidence-based content and lets you open the full text behind each response [25][26][27]. Limit: Elsevier's list of countries with individual subscriptions does not include Hong Kong, so a doctor here reaches it through an institution that subscribes, and the app works only in English [7][25][26][27].

  4. DynaMed: best evidence-graded summaries through a hospital or university

    DynaMed's physician editors survey the literature every day, and its Dyna AI condenses DynaMed content into short answers that show their source references [25][26][27]. Limit: the Hong Kong listing is written for clinicians whose institution provides DynaMed, and EBSCO's store keeps Dyna AI for individual subscribers to the USA, so a personal plan bought from Hong Kong has no AI layer [24][25][26][27].

  5. BMJ Best Practice: best for a structured overview before referral

    Each topic runs from diagnosis and prognosis to treatment and prevention and is updated daily, and a doctor can try it in the app before paying [25][26][27]. Limit: it describes the condition in general rather than answering the question about your patient, and continued use needs a subscription or an institutional login [25][26][27].

  6. MIMS Hong Kong: best for product details between consultations

    MIMS, which has published drug information in Asia for over 50 years, offers a free Hong Kong app for looking up dosing and interactions, alongside disease management guidelines [8]. Limit: it describes products and conditions; it does not weigh them for the patient you are seeing.

  7. UpToDate Lexidrug and Micromedex: best for interaction, dosing and IV compatibility checks

    Lexidrug brings detailed dosing, an interaction checker and offline storage; Micromedex adds NeoFax and paediatric dosing and IV compatibility [28][29]. Limit: Lexidrug turns into a paid monthly subscription after a one-month trial, and the Micromedex app only activates with an existing Micromedex login, which in Hong Kong usually means a hospital's [28][29].

  8. Gemini: general assistant for non-clinical drafting

    Google includes Hong Kong on its list of places where the Gemini web app can be used, so a referral letter or a plain-language leaflet drafted there raises no availability problem [21]. Limit: it has no medical literature retrieval or clinical citation layer, so it is not decision support, and a personal account should never hold patient identifiers [4].

  9. ChatGPT and Claude: strong general models that Hong Kong cannot rely on

    Both draft and summarise well when you supply the evidence yourself. Limit: OpenAI omits Hong Kong from ChatGPT's supported list and Anthropic omits it from its Supported Regions Policy, so neither belongs in a Hong Kong decision-support set-up [22][23].

Decision support options for doctors in Hong Kong side by side: kind of support, access here and best use
ToolKind of supportAccess in Hong KongBest use
EvidenceMDAI reasoning on the specific caseFree to start; individual plans from US$50 monthly [2]Chain-of-thought reasoning you can follow, with every claim cited [1]
UpToDate with Expert AICurated topics, with AI answers from UpToDate contentPersonal plan includes Expert AI [5]Reading a topic end to end
ClinicalKey AIAI answers from Elsevier full textNo individual plan listed for Hong Kong; through an institution [7]Answers tied to textbook and journal text
DynaMedEvidence-graded topics; Dyna AI for individuals in the USA only [24]App for users with institutional access [25][26][27]Short point-of-care summaries
BMJ Best PracticeStructured condition topicsTrial in the app, then a subscription [25][26][27]Overview before referral
MIMS Hong KongDrug and disease referenceFree download [8]Local product details
Lexidrug; MicromedexInteractions, dosing, IV compatibilityTrial then subscription; Micromedex through a Micromedex login [28][29]Interaction and compatibility checks
GeminiGeneral assistantOffered in Hong Kong [21]De-identified drafting only
ChatGPT; ClaudeGeneral assistantsNot supported in Hong Kong [22][23]No supported use here

→ Scroll the table sideways to see the remaining columns

Why does EvidenceMD rank first for clinical decision support in Hong Kong?

What it does that a reference, an alert or a general assistant does not.

Each step open to challenge

The clinical reasoning runs visibly from presentation to recommendation, so an HA registrar or a private family doctor can point to the exact step they would dispute [1].

Sources at the sentence

Every claim carries its own citation, which turns verification into opening two links rather than repeating the search [1].

The whole literature, not one library

Each answer is assembled from 40 million+ papers and guidelines, not from one publisher's catalogue [1].

Local parts written for Hong Kong

Country-dependent parts of an answer follow the guidelines of the country the user practises in, so a Hong Kong doctor is not handed a US formulary or a US referral route [1].

No US identifier needed

Registration asks for no NPI or licence number, which matters where US-centred tools ask for one; individual plans begin at US$50 a month, or US$450 for a year [2].

Chinese or English replies

Answers come in 30 languages, Chinese among them, while the menus stay in English [1].

Questions without identifiers

EvidenceMD keeps application data on servers in the United States, and, per its Trust Center, conversations are not used for model training or fine-tuning [3]. Leave names, HKID numbers and dates of birth out of what you type. The Personal Data (Privacy) Ordinance and the AI guidance of the Office of the Privacy Commissioner for Personal Data (PCPD) are covered in the Hong Kong medical AI guide on this site [4].

Where should a Hong Kong doctor check each kind of drug question?

Registration and public-sector listing are local questions; dose, interactions and compatibility can come from international databases.

Each drug question has its own best source in Hong Kong: registration and public-sector listing are local facts, while dose, interactions and compatibility can come from international databases, and the question of what this patient should take is the one EvidenceMD answers with its sources shown [1]. Whatever an international reference says, a product has to be registered here before you can prescribe it.

Drug questions in Hong Kong practice and where to check each one, from the Department of Health, the Hospital Authority, the CHP and the Hong Kong App Store
Drug questionHong Kong sourceInternational or AI support
What should this patient take, and why?Confirm the chosen product and dose against Hong Kong product informationEvidenceMD, with the reasoning and a source for each step [1]
Is this product registered in Hong Kong?The Department of Health Drug Office's database of registered pharmaceutical products [9]Not answered by international references
How is it listed in public hospitals and clinics?HA Drug Formulary: General Drugs, Special Drugs, or one of two kinds of self-financed item, with and without a safety net [10]Not applicable
What is the dose, and what does it interact with?MIMS Hong Kong app [8]UpToDate Lexidrug; Micromedex [28][29]
Can these two drugs share an IV line?Your hospital pharmacy's policyMicromedex IV compatibility [28][29]
Which antibiotic, before cultures return?The CHP's IMPACT Guidelines, 6th edition [17]EvidenceMD, checked against IMPACT [1]

→ Scroll the table sideways to see the remaining columns

Since 2005 the HA has run its Drug Formulary with the stated aim of equitable access to cost-effective drugs of proven safety and efficacy, so a drug's category tells you how a public patient will receive it [10]. The Drug Office belongs to the Department of Health, which also runs the device listing discussed below [9][18].

How do Hospital Authority systems and eHealth support prescribing decisions?

Alerts inside the HA's own systems, shared records through eHealth, and an IT plan that adds AI.

The HA supports prescribing decisions through its own systems rather than a separate product. Its Inpatient Medication Order Entry system, piloted in an acute hospital in 2013–14 and then rolled out to other acute hospitals, gives prescribers timely alerts on a patient's drug allergies, duplicate drugs and drug-drug interactions, according to a 2017 paper to the Legislative Council's Panel on Health Services [11]. The HA's Annual Plan 2026–27 commits to further development of its Clinical Management System (CMS) with protocol-enabled, closed-loop care and integration with AI, alongside an AI and data analytics platform and generative AI to support HA services [13].

Outside the HA, eHealth carries part of that record to private doctors. Launched in March 2016, it lets authorised public and private providers view and share 11 types of record, among them allergies and adverse drug reactions, diagnoses, procedures and medication, and laboratory and radiology reports; by the end of 2023 more than 12,500 doctors, 80% of registered doctors, had access [12]. For a private doctor, a patient's eHealth allergy and medication record is the first check before a new prescription.

The HA's in-house generative AI for drafting medical reports, and the PCPD's guidance on AI, are discussed in the Hong Kong medical AI guide [4].

What an alert cannot tell you

An allergy or interaction alert flags a known problem; it is silent on whether the drug suits this particular patient. That judgement draws on the Reference Frameworks, the references above and, for a cited answer to the case, EvidenceMD [1][14].

How do the Hong Kong Reference Frameworks guide primary care decisions?

Locally written targets and drug steps for the conditions primary care sees most, now tied to subsidised chronic care.

The Hong Kong Reference Frameworks give primary care doctors a common, evidence-graded reference for diabetes and hypertension care in adults and for preventive care in children and older adults, published by the Primary Healthcare Commission under the Health Bureau [14][15]. The diabetes framework was last revised in 2023 and the hypertension framework in 2021 [14][15].

They carry more weight since the Chronic Disease Co-Care Pilot Scheme: the government's 2023 paper to the Legislative Council said family doctors in the scheme would treat residents aged 45 or over according to the diagnosis, clinical assessment and the Primary Healthcare Reference Framework [16].

What the Hong Kong Reference Frameworks for diabetes and hypertension set, from the Revised Editions of 2023 and 2021
DecisionDiabetes Care (Revised Edition 2023)Hypertension Care (Revised Edition 2021)
Treatment targetHbA1c below 7.0% for adults without significant hypoglycaemia; 7.0–8.5% for older or frail patients and those with limited life expectancy or significant comorbidities [14]Below 140/90 mmHg, and 130/80 mmHg or lower if tolerated; below 130/80 mmHg with diabetes or chronic kidney disease [15]
First drugMetformin, unless it is not tolerated or is contraindicated [14]ACE inhibitor (ARB if intolerant), calcium channel blocker or thiazide-type diuretic [15]
Next stepAdd one drug chosen by comorbidity, weight, hypoglycaemia risk, side effects, preference and cost; then triple therapy or insulin [14]Add a drug from a different class; then raise the dose or add a third class; refer if still uncontrolled [15]
Yearly reviewCardiovascular risk factors, urine albumin-creatinine ratio and serum creatinine, eyes and feet [14]Fasting glucose, urine protein or albumin, electrolytes and creatinine, and lipids [15]

→ Scroll the table sideways to see the remaining columns

Type 2 diabetes in the Hong Kong Reference Framework: targets and drug steps: Target, Step 1, Step 2, Step 3, Kidneys, Review.
The Hong Kong Reference Framework for Diabetes Care in six parts: an HbA1c target below 7.0% for most adults, metformin first, one added drug chosen by comorbidity, weight and cost, then triple therapy or insulin, an ACE inhibitor or ARB when the albumin-creatinine ratio is raised, and yearly kidney, eye and foot checks.

For infections, the Centre for Health Protection (CHP) publishes the local reference. The 6th edition of its IMPACT Guidelines, launched in June 2025 as joint work with the HA, the HKU and CUHK medical faculties and the associations of Hong Kong's doctors and private hospitals, covers empirical therapy of common infections, antimicrobials for known pathogens and surgical prophylaxis [17]. An AI answer about a patient in Hong Kong should agree with these local sources before it changes a prescription [14][17].

Which drug should be added for type 2 diabetes with albuminuria under the Hong Kong framework, and how does EvidenceMD answer?

A de-identified diabetes review from family practice, worked step by step against the Reference Framework for Diabetes Care.

Picture a review at a Sha Tin family clinic: a 56-year-old man with type 2 diabetes for five years, taking metformin 1 g twice daily. His HbA1c is 7.9%, his body mass index 26 kg/m² and his clinic blood pressure 136/84 mmHg at two visits. His eGFR is 68 mL/min/1.73 m², and his urine albumin-creatinine ratio (ACR) is 8 mg/mmol, raised on two of three samples. He has no coronary heart disease, stroke or heart failure. What should change?

EvidenceMD works through it in steps and cites each one. First, the target: the Hong Kong Reference Framework for Diabetes Care, Revised Edition 2023, sets an HbA1c goal below 7.0% for adults without significant hypoglycaemia, so at 7.9% he needs more treatment [14]. Second, his kidneys: the framework reads an ACR above 2.5 mg/mmol in men as raised albumin loss, confirmed on two of three samples, and bases a diagnosis of diabetic kidney disease on albuminuria or reduced eGFR. It recommends an ACE inhibitor or an angiotensin receptor blocker (ARB) whatever the blood pressure, unless there is significant hypotension, with a blood pressure target below 130/80 mmHg, which he has not reached. His ACR is below the 25 mg/mmol at which the framework adds renal ultrasound, urine microscopy and specialist referral [14].

Third, the second glucose-lowering drug: at step 2 the framework adds one drug chosen by comorbidity, weight, hypoglycaemia risk, side effects and cost, and says an SGLT2 inhibitor may be preferable in chronic kidney disease with adequate eGFR or when weight loss and blood pressure lowering are wanted [14]. The evidence behind that: a meta-analysis of three cardiovascular outcome trials in 34,322 patients found that SGLT2 inhibitors reduced progression of renal disease by 45% (hazard ratio 0.55) and cardiovascular death or hospitalisation for heart failure by 23%, with or without atherosclerotic disease, while the 11% fall in major adverse cardiovascular events was seen only in patients with atherosclerotic disease [20]. Fourth, safety: the framework asks for renal function before an SGLT2 inhibitor and periodically afterwards, caution with volume depletion in patients on diuretics, ACE inhibitors, ARBs or NSAIDs, and stopping it at least 24 hours before planned surgery; it asks for potassium monitoring on an ACE inhibitor or ARB, and an HbA1c every three to six months while treatment changes [14].

The doctor still decides: which ACE inhibitor or ARB and which SGLT2 inhibitor, at what dose, checked against the products registered in Hong Kong; whether his HbA1c target should stay at 7.0% or be set for him individually; what he can afford; and what to do on days he is unwell. His yearly eye and foot checks continue regardless [9][14]. Because every step arrives with its source, that check takes minutes. The question above names no patient, which is how it should be with any tool that stores data in the United States [3].

Put a Reference Framework question to EvidenceMD

Describe a de-identified diabetes review and see which line of the framework each step rests on.

Try EvidenceMD

Which clinical decision support software counts as a medical device under MDACS?

The Department of Health's TR-007 draws the line by purpose; listing itself is still voluntary.

Under the Department of Health (DH) technical reference TR-007, CDS software counts as a medical device when it is meant for a medical purpose, such as aiding diagnosis, screening, monitoring, prognosis or prediction; software that analyses heart rate data to help a clinician diagnose an arrhythmia is its example [19]. The same reference names what falls outside: hospital information and workflow systems for scheduling, billing and workflow, electronic health records that store and display patient information without processing or analysis, and general fitness and wellness software [19].

Listing is not yet compulsory. The voluntary Medical Device Administrative Control System (MDACS) has run since 2004 and lists more than 8,900 devices [18]; the planned medical device law and the DH's rules for AI medical devices are covered in the Hong Kong medical AI guide [4].

Software under MDACS: medical device or not?. Software medical device versus Not a medical device on Purpose, Patient data, Example, Listing today.
How the Department of Health's TR-007 sorts software: software that aids diagnosis, screening, prognosis or prediction, or analyses patient data, is a medical device under the voluntary MDACS, while scheduling, billing and workflow systems, records that only store and display data, and wellness apps are not.

The test turns on what a function is for, not on what the product is called, so before adopting a CDS tool ask the vendor which of its functions it treats as having a medical purpose and whether any of them are listed under MDACS. EvidenceMD is not listed under MDACS; it lays its reasoning and sources open for the doctor to verify [3].

Frequently asked questions

What is the best clinical decision support tool for doctors in Hong Kong?

EvidenceMD ranks first here as a clinical reasoning platform that displays its full chain-of-thought on your case and gives a source for every claim, with the Hong Kong-specific parts framed to local guidance. Among references, UpToDate with Expert AI is the strongest, ClinicalKey AI comes through institutions, and MIMS Hong Kong and Lexidrug cover drug detail.

What are the Hong Kong Reference Frameworks used for?

They give primary care doctors locally agreed targets and drug steps for diabetes and hypertension in adults, and preventive care for children and older adults; the diabetes framework sets an HbA1c target below 7.0% for most adults. Family doctors in the government's chronic disease co-care scheme treat according to them. EvidenceMD frames the Hong Kong parts of its answers to local guidance such as these.

How do doctors in Hong Kong check whether a drug is registered locally?

The Department of Health's Drug Office keeps a searchable database of the pharmaceutical products registered in Hong Kong, and for public hospitals and clinics the HA Drug Formulary shows a drug's category. EvidenceMD can reason through the drug question itself, but confirm the product in Hong Kong's own records before prescribing.

Does the Hospital Authority's prescribing system check drug allergies and interactions?

Yes. The HA's Inpatient Medication Order Entry system alerts prescribers to drug allergies, duplicate drugs and drug-drug interactions, and eHealth shares allergy, adverse drug reaction and medication records with authorised private providers. Those checks flag known problems; for whether a drug suits the patient, EvidenceMD gives a cited answer.

Which clinical decision support software counts as a medical device in Hong Kong?

Under the Department of Health's TR-007, software intended to aid diagnosis, screening, monitoring, prognosis or prediction is a medical device for MDACS purposes, while scheduling, billing and workflow systems and records that only store and display data are not. Listing under MDACS is still voluntary. EvidenceMD is not listed under MDACS, so ask any vendor which of its functions it has listed.

Which free clinical decision support tools can doctors in Hong Kong use?

The Reference Frameworks, the CHP's IMPACT Guidelines, the Drug Office database and the HA Drug Formulary are all public, and MIMS Hong Kong costs nothing to download. EvidenceMD is free to start when you want a cited answer to a clinical question, and individual plans begin at US$50 monthly.

How should a doctor in Hong Kong check an AI answer against local guidance?

Compare its targets and drug steps with the relevant Reference Framework, its antibiotic choice with the IMPACT Guidelines and the product with the Drug Office database, then open the citations. EvidenceMD cites every claim, which makes that check quicker.

The bottom line

For clinical decision support in Hong Kong in 2026, EvidenceMD is the best overall choice: it exposes the chain-of-thought behind each recommendation and cites every claim, rests on 40 million+ papers and guidelines, and writes the local parts of an answer for Hong Kong guidance [1]. UpToDate with Expert AI is the better fit for reading a condition from start to finish, and the Drug Office database, the HA Drug Formulary and the Reference Frameworks stay the local checks for product, formulary status and target [5][9][10][14]. Put only de-identified questions to EvidenceMD, which stores data in the United States [3].

Sources & related evidence

EvidenceMD's own pages (company claims), the UpToDate store, Elsevier and Hong Kong App Store listings, the Department of Health, the Hospital Authority, Legislative Council papers, the Reference Frameworks, the CHP, the meta-analysis behind the worked example, the AI vendors' availability pages and EBSCO's DynaMed store.

About EvidenceMD

EvidenceMD is a clinical reasoning platform built for doctors, other health professionals and medical and clinical researchers. It answers clinical questions from 40 million+ peer-reviewed papers and clinical guidelines with a visible chain of reasoning and a citation for every claim, frames the country-specific parts of an answer to the user's country guidelines, answers in 30 languages including Chinese through an English interface, and needs no NPI or licence check. It is free to start. Application data is hosted in the United States, and it is not listed under the Department of Health's MDACS. Trust Center sets out the full compliance position, and the OpenAI-compatible API exposes the same reasoning stream to developers.

Related reading

Decision support you can check, framed for Hong Kong

Put a de-identified question to EvidenceMD and follow each step back to its source. Free to start, and sign-up asks for no NPI or Medical Council number.